IR
Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases
Disclosure
Total of 10posts
| Number | Title | Person with Duty to Submit | Receipt Date |
|---|---|---|---|
| 10 | Decision on Asset Revaluation(Voluntary Disclosure) | 2023-11-16 | |
| 9 | Material Management Information related to Judgment of Investment(Study Results)(항암면역치료백신 BVAC-C의 제2a상 임상시험) | 2023-09-21 | |
| 8 | Additional Listing(유상증자(구주주배정)) | KOSDAQ STOCK MKT. | 2023-09-20 |
| 7 | Results of issuance(Voluntary Disclosure) | 2023-09-08 | |
| 6 | Results of Subscription (Voluntary Disclosure) | 2023-09-07 | |
| 5 | Results of Subscription (Voluntary Disclosure) | 2023-09-04 | |
| 4 | [Revised]Decision on Paid-in Capital Increase(주주우선공모증자) | 2023-08-29 | |
| 3 | Material Management Information related to Judgment of Investment(IND Approval Determination)(COVID-19 예방 백신 AdCLD-CoV19-1 OMI의 제3상 임상시험 계획(IND) 승인) | 2023-07-21 | |
| 2 | Ex-Rights(유상증자) | KOSDAQ STOCK MKT. | 2023-07-17 |
| 1 | [Revised]Decision on Paid-in Capital Increase(주주우선공모증자) | 2023-07-17 |
